Fri, October 11, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. TH
Healthcare
Facebook Twitter Linkedin

Theratechnologies Inc. (TSX:TH)

1.63 CAD

0.000 0.000%
Last Updated at: 2024-10-09T17:32:00Z

Theratechnologies Inc.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

2015 Peel Street, Montreal, QC, Canada, H3A 1T8

514 336 7800

https://www.theratech.com

Employees: 144

Key Executives

Sr. No. Name Title Year Born
1. Mr. Paul Lévesque Pres, CEO & Director 1964
2. Mr. Philippe Dubuc M.B.A., MBA Sr. VP & CFO 1967
3. Dr. Christian Marsolais Ph.D. Sr. VP & Chief Medical Officer 1963
4. Mr. John Leasure Global Commercial Officer 1965
5. Ms. Elif McDonald Sr. Director of Investor Relations NA
6. Mr. Jocelyn Lafond L.L.M., LL.B. Gen. Counsel & Corp. Sec. 1968
7. Mr. Denis Boucher B.A., L.L.B. VP of Communications & Corp. Affairs 1966
8. Hon. Andre Dupras M.Sc. VP of HR 1964

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
FRX

Fennec Pharmaceuticals Inc

 -0.250 4.032% 6.01 0.000 33.333 29.100 84.571 30.471 -23.399
SVA

Sernova Corp

 +0.005 1.923% 0.265 0.000 0.000 0.000 7.952 0.000 -4.410
EPRX

Eupraxia Pharmaceuticals Inc

 -0.090 2.821% 3.3 0.000 0.000 0.000 8.396 0.000 -3.916
ONC

Oncolytics Biotech Inc

 +0.080 4.624% 1.72 0.000 0.000 0.000 3.997 0.000 -2.314

Income Statement

(Currency in CAD)
Breakdown 30-11-2022 30-11-2021 30-11-2020 30-11-2019 30-11-2018
Income Before Tax -46.794M -31.662M -22.651M -12.496M -5.78M
Minority Interest - - - - -
Net Income -47.237M -31.725M -22.667M -12.547M -4.529M
Selling General Administrative 17.356M 14.616M 12.23M 8.33M 5.686M
Gross Profit 53.778M 46.563M 39.151M 37.14M 31.126M
Reconciled Depreciation 12.471M 8.748M 8.52M 7.495M 4.148M
Ebit -39.908M -25.236M -17.957M -7.455M -3.301M
Ebitda -27.156M -16.324M -9.178M 0.04M 0.847M
Depreciation And Amortization 12.752M 8.912M 8.779M 7.495M 4.148M
Operating Income -39.908M -25.236M -17.957M -7.455M -3.416M
Other Operating Expenses 119.965M 95.059M 84.01M 71.729M 47.515M
Interest Expense 6.497M 5.664M 5.362M 4.99M 2.479M
Tax Provision 0.443M 0.063M 0.016M 0M -1.269M
Interest Income 7.208M 0.195M 4.654M 3.944M 2.371M
Net Interest Income -6.216M -6.426M -5.103M -3.932M -2.203M
Income Tax Expense 0.443M 0.063M 0.016M 0.051M -1.252M
Total Revenue 80.057M 69.823M 66.053M 63.216M 44.099M
Total Operating Expenses 93.686M 71.799M 57.108M 45.653M 34.542M
Cost Of Revenue 26.279M 23.26M 26.902M 26.076M 12.973M
Total Other Income Expense Net -6.886M -6.426M -4.694M -5.041M -2.365M
Net Income From Continuing Ops -47.237M -31.725M -22.667M -12.496M -4.529M
Net Income Applicable To Common Shares -47.237M -31.725M -22.667M -12.496M -4.7M

Balance Sheet

(Currency in CAD)
Breakdown 30-11-2022 30-11-2021 30-11-2020 30-11-2019 30-11-2018
Total Assets 93.26M 119.212M 100.142M 117.555M 111.253M
Intangible Assets 15.009M 23.829M 31.852M 39.684M 15.138M
Other Current Assets 8.268M 11.485M 5.709M 4.511M 2.885M
Total Liab 115.831M 101.452M 96.918M 92.721M 76.198M
Total Stockholder Equity -22.571M 17.76M 3.224M 24.834M 35.055M
Other Current Liab 36.09M 58.066M 23.934M 23.968M 11.273M
Common Stock 338.751M 335.752M 287.312M 287.035M 252.483M
Capital Stock 338.751M 335.752M 287.312M 287.035M 252.483M
Retained Earnings -382.649M -335.248M -300.129M -277.462M -230.686M
Good Will - - - - -
Other Assets 1.792M 0.621M - - -
Cash 23.856M 20.399M 12.737M 28.661M 39.045M
Cash And Equivalents 9.214M 19.955M 8.031M 11.964M 9.691M
Total Current Liabilities 114.279M 45.076M 41.919M 37.144M 26.904M
Current Deferred Revenue 0.038M 0.054M 0.05M 0.07M 0.027M
Net Debt 42.855M 36.346M 42.646M 22.08M 10.25M
Short Term Debt 65.265M 0.463M 0.425M 20.551M 0M
Short Long Term Debt 64.789M - - - -
Short Long Term Debt Total 66.711M 56.745M 55.383M 50.741M 49.294M
Other Stockholder Equity 20.942M 17.3M 16.522M 15.24M 12.271M
Property Plant Equipment 3.089M 2.854M 3.483M 1.071M 0.101M
Total Current Assets 73.37M 91.908M 64.807M 76.181M 73.696M
Long Term Investments - - 0M 0.619M 5.207M
Short Term Investments 9.214M 19.955M 8.031M 11.964M 9.702M
Net Receivables 12.344M 10.928M 13.185M 10.116M 10.966M
Long Term Debt 0M 54.227M 52.403M 55.311M 49.233M
Inventory 19.688M 29.141M 25.145M 20.929M 11.098M
Accounts Payable 12.886M 15.526M 17.51M 13.106M 15.604M
Accumulated Other Comprehensive Income 0.385M -0.044M -0.481M 0.021M 0.986M
Non Currrent Assets Other 1.792M 0.621M - 12.204M 17.11M
Non Current Assets Total 19.89M 27.304M 35.335M 41.374M 37.556M
Capital Lease Obligations 1.922M 2.518M 2.98M - -
Long Term Debt Total 1.446M 56.282M 54.958M 55.311M 49.233M

Cash Flow

(Currency in CAD)
Breakdown 30-11-2022 30-11-2021 30-11-2020 30-11-2019 30-11-2018
Investments 8.682M -12.116M 4.776M -0.13M -10.691M
Total Cashflows From Investing Activities 8.682M -12.454M 4.776M -0.13M -9.918M
Total Cash From Financing Activities 9.656M 34.557M -7.229M -6.807M 46.889M
Net Income -47.237M -31.725M -22.667M -12.496M -4.529M
Change In Cash 3.457M 7.662M -15.924M -10.336M 37.719M
Begin Period Cash Flow 20.399M 12.737M 28.661M 38.997M 1.326M
End Period Cash Flow 23.856M 20.399M 12.737M 28.661M 39.045M
Total Cash From Operating Activities -14.692M -14.477M -13.554M -3.391M -0.334M
Depreciation 12.471M 8.748M 8.52M 7.495M 4.148M
Other Cashflows From Investing Activities 9.667M -0.172M 0.361M 1.202M 0.754M
Dividends Paid - 0M 0M 0M -
Change To Inventory 8.991M -4.187M -4.872M -9.861M -3.901M
Sale Purchase Of Stock 2.981M 47.339M 0.145M 0.11M 0.633M
Other Cashflows From Financing Activities 36.047M -10.81M -6.661M -6.807M 57.069M
Capital Expenditures 0.985M 0.166M 0.032M 3.622M 0.039M
Change In Working Capital 13.017M 0.242M -6.274M -3.662M -0.037M
Other Non Cash Items 2.742M 6.326M 5.44M 4.185M 0.509M
Free Cash Flow -15.677M -14.643M -13.586M -7.013M -0.374M

No data found

Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App